THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY
INFORMATION and GUIDELINES FOR AUTHORS (updated, September 2017)

TABLE OF CONTENTS
• Description of Journal
• Abstracting and Indexing
• Editorial Board
• Guidelines for Authors

DESCRIPTION OF JOURNAL
THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY (JCSO) is a peer-reviewed journal that features Original Research and Review articles, Case Reports, and How We Do It essays in clinical oncology and supportive care. The journal is web-based and publishes a bimonthly digital issue that is available as an app. Its readership is comprised of practice-based medical oncologists and hematologists, supportive care specialists, nurses and physician assistants, and pharmacists – that is, the oncology care team. JSCO has become a vital clinical forum and resource in the supportive and community oncology practice settings. A recent survey showed that its readers are highly engaged and value the content and information we provide, with almost 60% reporting that they have incorporated information from our articles into patient care. JCSO was formed with the merger in January 2014 of the former Journal of Supportive Oncology and its sister publication, Community Oncology.

Submissions to the Journal are made at http://www.editorialmanager.com/jso/default.asp

Visit the website at http://www.jcso-online.com

ABSTRACTING AND INDEXING
EMBASE, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Scopus

EDITORIAL BOARD
Editor-in-Chief, David H Henry, MD, FACP

Associate Editors, Jame Abraham, MD; Linda D Bosserman, MD, FACP; Howard A Burris III; David Cella, PhD; Kevin B Knopf, MD; Thomas Strouse, MD

Editorial Board
Janet L Abrahm, MD
Donald Abrams, MD
Athanassios Argiris, MD
Anthony Back, MD
Johanna Bendell, MD
Charles L Bennett, MD, PhD, MPP
Ann M Berger, MSN, MD
Donna L Berry, MD
Diane Blum, MSW
Ralph V Boccia, MD
Matt Brow
Leslie T Busby, MD
Toby C Campbell, MD
Barrie R Cassileth, PhD
Sant P Chawla, MD, FRACP
Harvey Max Chochinov, MD
Nessa Coyle, PhD, NP, FAAN
Larry D Cripe, MD
Mellar P Davis, MD, FCCP, FAAN
Daniel G Haller, MD
Paul R Helft, MD
David MJ Hoffman, MD
Jimmie Holland, MD
Thomas Julian, MD
Vivek Kavadi, MD
Kartik Konduri, MD
Mark G Kris, MD
Shaji Kumar, MD
Stuart M Lichtman, MD
D Andrew Loblaw, MD, MSc, FRCP
Charles L Loprinzi, MD
GUIDELINES FOR AUTHORS

INTRODUCTION
The JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY publishes peer-reviewed articles and commentaries on all aspects of clinical and supportive oncology practice and evidence-based practices for treating and caring for patients with cancer.

Please note the following:
- Papers submitted to the Journal should follow the style guidelines of the AMA Manual of Style (10th edition), with notable exceptions in the presentation some of the References (see page 10).
- Papers that exceed the stipulated word counts or number of references, tables, or figures will be returned to the author(s) for editing before the paper is sent out for review.
- Papers in which the references do not follow style as per page 10 will also be returned to the author for revision.
- All pages of the manuscript should be numbered consecutively, beginning with the title page.

TYPES OF ARTICLES
Article types include original research reports of clinical and supportive/palliative care studies in practice-based settings, literature reviews, How We Do It reports on best practices, Case Reports, and Letters to the Editors.

Below is a summary of the categories of papers for The JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY.

Papers that exceed the stipulated word counts and or number of references will be returned to the author for editing before being sent for review.

Original Reports
These are reports on randomized trials, intervention studies, cohort studies, case-control studies, epidemiologic assessments, surveys, cost-effectiveness analyses, and studies of screening and diagnostic tests as they pertain to the diagnosis and treatment of cancer with a focus on real-world patient outcomes, the management of treatment side effects (psychological and physical), patient outcomes and quality of life, supportive and palliative care, and the quality and cost effectiveness of care. Prospective studies are preferred over retrospective, single database analyses.
Findings from Original Reports MUST NOT BE INFLUENCED BY THE AUTHORS’ OR FUNDER’S OPINIONS (AMA 1.2). Funder advocation should not be part of the Report.

Papers with promotional intent will not be sent out for review.

Original research reports will:

- Be no more than 4,500 words (including a structured abstract, references, and figure titles and legends).
- Have a structured abstract of no more than 250 words, under the following subheads: Background, Objective, Methods, Results, Limitations, Conclusions, Funding/sponsorship.
- Have a title (headline) of no more than 75 characters, including spaces.
- Have no more than 5 tables and/or figures (AMA chapter 4).
- Include figures (if any) that are submitted as separate, high-resolution PNG or JPEG files (see page 12).
- Limit figures, clinical images, and tables to those necessary to highlight key data.
- Be arranged as follows: title page; structured abstract and key words; abbreviations list; text; acknowledgments (if applicable); references; figure titles and legends; and tables.
- Have 45 or fewer references, which will be in AMA style (AMA chapter 3) – with notable exceptions in the presentation some of the references (see page 10).
- Begin page numbering with the title page.
- Either provide sex-specific data (when appropriate) in describing outcomes of epidemiologic analyses or clinical trials, or specifically state that no gender-based differences were present.

Review Papers

The editors will consider invited and uninvited review papers. These manuscripts gather and summarize information from current literature and data sources on clinical or supportive and palliative care topics. They should do the following:

- Focus on novel approaches and cutting-edge therapies or supportive and palliative care, as well as diagnoses, prognoses, disease and symptom management, and/or prevention strategies.
- Include studies drawn from multiple research sources or platforms, print and web-based. Single-source reviews will not be considered for publication.
- Clearly outline the review questions.
- Include critical assessments of the studies.
- Explore their potential for changing cancer treatment.

Review articles are often used as guides in the practice setting, and therefore they must be systematic, must include relevant data, and MUST NOT BE INFLUENCED BY THE AUTHORS’ OR FUNDER’S OPINIONS (AMA 1.2). Funder advocation should not be part of the Review.

The search and selection processes for research sources, such as databases, should be described in the manuscript. There must be multiple research sources should be as current as possible, preferably with the search having been conducted within a few months of submission. Authors should detail in their cover letters how their review differs from existing reviews on the subject.

Review and state-of-the-art manuscripts will:

- Be no more than 5,000 words (including an unstructured abstract, reference list, tables, and figure titles and legends).
- Have an unstructured abstract of 250 or fewer words (AMA 2.5.2-2.5.3).
- Have a title (headline) of no more than 75 characters, including spaces.
- Have no more than 4 tables and/or figures, which should be submitted as separate files.
- Include figures (if any) that are submitted as separate, high-resolution PNG or JPEG files (see page 12).
Limit figures, clinical images, and tables to those necessary to highlight key data.
Be arranged as follows: title page; structured abstract and key words; abbreviations list; text; acknowledgments (if applicable); references; figure titles and legends; and tables.
Have 50 or fewer references, which will be in AMA style (AMA chapter 3) – with notable exceptions in the presentation some of the references (see page 10).
Begin page numbering with the title page.

How We Do It articles
The editors will consider invited and uninvited How We Do It articles. These manuscripts should focus on your organization’s best practices. They should do the following:
- Focus on novel approaches and cutting-edge therapies or supportive and palliative care, as well as diagnoses, prognoses, disease and symptom management, and/or prevention strategies.
- Include critical assessments thereof.
- Explore their potential for changing cancer treatment.

How We Do It manuscripts will:
- Be no more than 4,500 words (including an unstructured abstract, reference list, tables, and figure titles and legends).
- Have an unstructured abstract of 250 or fewer words (AMA 2.5.2-2.5.3).
- Have a title (headline) of no more than 75 characters, including spaces.
- Have no more than 4 tables and/or figures, which should be submitted as separate files.
- Include figures (if any) that are submitted as separate, high-resolution PNG or JPEG files (see page 12).
- Limit figures, clinical images, and tables to those necessary to highlight key data.
- Be arranged as follows: title page; structured abstract and key words; abbreviations list; text; acknowledgments (if applicable); references; figure titles and legends; and tables.
- Have 30 or fewer references, which will be in AMA style (AMA chapter 3) – with notable exceptions in the presentation some of the references (see page 10).
- Begin page numbering with the title page.

Case Reports
These reports usually describe a step-by-step approach to clinical and/or supportive decision making in the diagnosis and treatment of a patient who has an unusual or complicated presentation or diagnosis. They can be accompanied by a brief review of pertinent, current literature.

A case letter will:
- Be limited to 2,000 words (including references, tables, and figure titles and legends).
- Have an unstructured abstract of 50 or fewer words.
- Have a title (headline) of no more than 75 characters, including spaces.
- Begin with a brief summary of literature before the case details are presented.
- Have no more than 1 table and/or 4 figures.
- Include figures (if any) that are submitted as separate, high-resolution PNG or JPEG files (see page 12).
- Have no more than 15 references, which will be in AMA style (AMA chapter 3) – with notable exceptions in the presentation some of the references (see page 10).
- Adequately de-identify all patient information. If identifying information or figures are included, express written permission from the patient(s) must be provided at the time of manuscript submission.
- Begin page numbering with the title page.
Letters to the Editor

Letters to the Editor should focus on a specific article that has been published in THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY.

A letter to the editor will:
- Have no more than 3 authors, and will provide the full name, academic degrees, and a single institutional affiliation for each author.
- Provide disclosures, if relevant to the topic of the letter, for each letter author.
- Provide the e-mail address for the corresponding letter author.
- Be no more than 400 words long.
- Have no more than 5 references, 1 of which must be the relevant THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY article, and, which will be in AMA style (AMA chapter 3) – with notable exceptions in the presentation some of the references (see page 10).
- Have a title of 5-7 words (no more than 35 characters, including spaces).
- Begin page numbering with the title page.

Letters will be sent for response to the authors of the original article. This response may be published or sent directly to the commentator at the discretion of the editor. Letters will be published at the discretion of the editors, and are subject to abridgement and editing for style and content. Questions or comments that could be addressed directly to authors of the original article (including complaints about missed citations) should be sent directly to those authors.

BEFORE YOU BEGIN

Ethics in Publishing

Studies should be in compliance with human studies committees of the authors’ institution(s) and US Food and Drug Administration guidelines.

Studies must be performed with the participants' written informed consent. Authors must provide the details of this procedure and indicate that the institutional committee on human research has approved the study protocol. If radiation is used in a research procedure, the radiation exposure must be specified in the Methods section.

Studies on patients or volunteers require ethics committee approval and informed consent, which should be documented in your paper. Patients have a right to privacy. Therefore, identifying information — including patients’ images, names, initials, or hospital numbers — should not be included in videos, recordings, written descriptions, photographs, and pedigrees unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). Written consents must be provided to the editorial office on request. Even where consent has been given, identifying details should be omitted if they are not essential. If identifying characteristics are altered to protect anonymity, such as in genetic pedigrees, authors should provide assurance that alterations do not distort scientific meaning, and editors should so note. If such consent has not been obtained, personal details of patients included in any part of the paper and in any supplementary materials (including all illustrations and videos) must be removed before submission.

Human and animal rights

If the work involves the use of human participants, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans; uniform requirements for manuscripts submitted to biomedical journals. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with humans. The privacy rights of human subjects must always be observed.
All animal experiments should comply with the National Research Council (US) Guide for the Care and Use of Laboratory Animals (8th edition, revised 2011), OR the ARRIVE guidelines and in accordance with the UK Animals (Scientific Procedures) Act, 1986 and associated guidelines, OR the EU Directive 2010/63/EU for animal experiments. The authors should clearly indicate in the manuscript that such guidelines have been followed.

Conflict of Interest
THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY requires all authors to acknowledge in the Comments section of Editorial Manager (http://www.editorialmanager.com/jso/default.asp) all funding sources that supported their work, as well as all institutional or corporate affiliations of the authors. The title page must also include a publishable statement disclosing any associations (current and over the past 5 years) that might pose a conflict of interest. These include but are not limited to employment; royalties; consultant arrangements with a commercial entity; stock or other equity ownership; stock options; patent licensing arrangements; payments for conducting or publicizing a product or study; or consulting relationships with investment companies. In addition, authors are required to disclose similar associations with companies that make a competing product. When no conflicting or competing interests are present, this should be indicated in the publishable disclosure statement.

If the authors have competing or conflicting interests that cannot be disclosed in publishable statements, authors should list them in the Comments section of Editorial Manager. They should also explain these interests as well as the reason for the need for confidentiality in a statement to the Editor. The Editor asks each reviewer to disclose any competing interests or conflicts of interest that might interfere with objectivity (or to recuse him- or herself from acting as a reviewer). The Editors and members of the editorial staff will ensure that all conflicts are appropriately resolved. Conflicts that cannot be appropriately resolved will result in rejection of the manuscript or review. Undisclosed conflicts may result in sanctions, to include published statements of retraction or removal of a manuscript from the archived journal table of contents.

Submission Declaration
Submission of an paper implies that the work described has not been previously published (except in the form of an abstract or as part of a published lecture or academic thesis), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere including electronically in the same form, in English or in any other language, without the written consent of the copyright-holder.

Authorship
Each author must have contributed significantly to the submitted work. If there are more than four authors, the contribution of each must be substantiated in the cover letter. If authorship is attributed to a group (either solely or in addition to one or more individual authors), then all members of the group must meet the full criteria and requirements for authorship. To save space, if group members have been listed in THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, the article should be referenced rather than reprinting the list.

The editors consider authorship to include all of the following:

- Conception and design or analysis and interpretation of data, or both.
- Drafting of the manuscript or revising it critically for important intellectual content.
- Final approval of the manuscript submitted.

Participation solely in the collection of data does not justify authorship but may be appropriately acknowledged in the Acknowledgment section.

Manuscripts must be submitted with a cover letter that includes the following:

- A statement that the paper is not under consideration elsewhere.
Changes to Authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts:

- **After acceptance but before online publication.** Requests to add or remove an author, or to rearrange the author names, must be sent to the Managing Editor from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged, and (b) written confirmation (e-mail, fax, letter) from all of the authors that they agree with the addition, removal, or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Requests that are not sent by the corresponding author will be forwarded by the Managing Editor to the corresponding author, who must follow the procedure as described above. Note that publication of the accepted manuscript in an online issue is suspended until authorship has been agreed upon.

- **After acceptance and online publication.** Any requests to add, delete, or rearrange author names in an article published in an online issue will follow the same policies as noted above, and will result in a corrigendum.

Copyright
Upon acceptance of an paper, authors will be asked to complete a “Journal Publishing Agreement. Acceptance of the agreement will ensure the widest possible dissemination of information. An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a ‘Journal Publishing Agreement’ form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. There are preprinted forms for use by authors in these cases.

Retained Author Rights
As an author, you (or your employer or institution) retain certain rights; for details, please refer to http://www.editorialmanager.com/jso/default.asp.

Role of the Funding Source
You are requested to identify who provided financial support for the conduct of the research and/or preparation of the paper, and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication. If the funding source(s) had no such involvement, then this should be stated.
PREPARING YOUR MANUSCRIPT

Language
Please write your text in clear, precise English. (American or British usage is accepted, but not a mixture of these.) Active tense is almost always preferred to passive tense.

Word-Processing Software
It is important that the file be saved in the native format of the word processing program used. Microsoft Word documents are preferable.

Text Formatting – Simplicity, simplicity, simplicity!
• Basic format: Single-column, double spaced, 10-point font size.
• Right-hand margins: Unjustified (ragged).
• Follow AMA style for boldface type, italics, sub- and superscripts, and the like.
• Tables with grids: Use a grid for each row.
• Tables without grids: Use tabs (not spaces) to align columns.

DO NOT use the following in your manuscripts:
• Word-processing style tags.
• Forced section breaks or page breaks.
• Automatic footnotes and/or running heads
• Automatic referencing.
• Hyperlinks. Please no hyperlinks.
• Text justification.
• Automatic hyphenation.

Front Matter
Title Page. Please include the following elements on the title page. Begin numbering the pages of the manuscript with the title page as page 1.

Manuscript title. The title should be no longer than 75 characters, including spacing.

Author names and degrees. Please note the following:
• For authors’ full names, follow AMA 2.2.1.
• The first name is written out in full, and the middle initial is optional as per author preference and it does not take a period after it.
• If the last name is ambiguous (eg, a nonwestern name or a hyphenated double name), indicate the surname clearly by putting it in bold typeface. This is important for online tagging.
• For authors’ academic degrees, follow AMA 2.2.3. The policy of this journal is to list the authors’ highest academic and/or professional degrees (more than one are acceptable if they are in different fields), as well as specialized professional certifications, degrees, and licensure, as noted in AMA 2.2.3. Degrees do not take periods between the letters, eg, MD, PhD, RN.
• For multiple authors, ensure that the order of names reflects the order the authors agreed upon before the manuscript submission. See AMA 2.2.4 for samples.
• Use superscript alphabetical letters after each author’s name to refer to corresponding superscripted affiliations.

Firstname1 Initial1 Lastname1, MD, PhD, Firstname2 Lastname2, MD, MPH, Firstname3 Initial3 Lastname3 III, MD, MBA, and Firstname4 Lastname4
Author affiliations. Follow AMA 2.3.3, with these 2 exceptions:

- Exception: Precede each affiliation with a superscript letter of the alphabet that corresponds to the affiliated author’s name in the byline. One superscript letter may correspond to more than one author name.
- Exception: Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.

Corresponding author. See AMA 2.10.4 for guidance and samples. The corresponding author must inform the Managing Editor of any changes in contact information.

Abstract. Original research reports and review articles require concise, factual structured or unstructured abstracts. Follow AMA 2.5 guidelines, with the following requirements that are specific to THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY:

- A structured abstract (original research papers, 250 words maximum) briefly states the purpose of the research, the principal results, and major conclusions. It is organized under the following headings: Background, Objective, Methods, Results, Limitations, Conclusions, Funding/Sponsorship.
- An unstructured abstract for How We Do It and state-of-the-art and review papers (250 words maximum, including Funding/Sponsorship information) briefly summarizes the review.

An abstract is often presented separately from the article; thus it must be able to stand alone, so references in the abstract should be avoided. If a reference is essential, then it should be given in full. Likewise, all abbreviations must be defined at first mention in the abstract, even if they are also defined in the article’s main body, and the abstract should include information about funding and sponsorship.

Keywords. Immediately after the abstract, provide a maximum of 6 keywords. These keywords will be used for indexing purposes. See AMA 2.6 for guidance. In addition:

- Use American spelling.
- Separate the keywords with commas.
- Avoid general and plural terms.
- Avoid multiple concepts (eg, “and” and “of”).
- Only abbreviations firmly established in the field may be eligible.

Main Body of Running Text
There is no subhead for the introduction to the paper. The introduction should be 2-3 paragraphs long. It should state the objectives of the work and provide an adequate background and context for the article. It should not include a detailed literature survey or a summary of the results.

Methods. This section should be presented under the subheading “Methods” and should describe study design; the topic that is being studied; details about the participants; inclusion and exclusion criteria; interventions; outcome measures and observations; and a statistical analysis. It should provide sufficient detail to allow the work to be reproduced. Methods that have already been published should be indicated by a reference; only relevant modifications should be described. See AMA 2.8 for guidance.

Results. This section should be presented under the subheading “Results” and should present the data and evidence to support the findings. Their presentation should be written clearly, concisely, and
there should be specific to the research hypothesis. Referring the readers in the Results section to tables and/or figures alone is not an acceptable substitute for the presentation of data as outlined in the preceding sentences. See AMA 2.8 for guidance.

Discussion. This section should be presented after the “Results” section explore the significance of the results of the work; do not repeat the results. Avoid extensive citations and discussion of published literature. Instead, address the research hypothesis, and compare your findings with those of similar studies. Also, discuss generalizability of results, study limitations, unexpected findings (and possible explanations for them), and suggested future studies. New results not already mentioned in the Results section cannot be introduced in the Discussion section. The final sentence or two of the discussion section should be reserved for your conclusions.

Acknowledgments
Please refer to AMA 2.10 for guidance. Collate acknowledgments on the title page, with the author(s) and corresponding author’s information so that the information is not included in the version of the manuscript that is sent out for blind review. List here those individuals who provided help during the research (eg, writing, or editorial or statistical assistance). After the manuscript has been accepted for publication, the editor will place the Acknowledgments information in a separate section at the end of the paper before the references.

References
Please consult AMA chapter 3 for a comprehensive guide to reference styles, including samples. Manuscripts that do not follow AMA guidelines or the exceptions to AMA guidelines listed below will be returned to the author(s) for revision on an acceptance-pending basis.

In the running text, please note the following:
- **THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY** does not use parenthetical references in running text (as described in AMA 3.3). Please do not submit your paper with the references done in this way.
- Reference citations in the running text (“callouts”) should be denoted by superscript numbers in consecutive order (AMA 3.5, 3.6).
- Make sure that every callout in the running text corresponds with, in consecutive order, a reference in the reference list (and vice versa).
- Superscript citation numbers are always placed **after** punctuation marks:

  “… according to study findings.¹⁴,⁷,¹⁰ (Please note the placement of the period.)

In the reference list, please format author names according to AMA 3.7 and 3.8:
- 1 author: Lastname AB.
- 2 authors: Lastname AB, Lastname CD Jr.
- 3 authors: Lastname AB, Lastname CD Jr, Lastname EF.
- 4 authors: Lastname AB, Lastname CD Jr, Lastname EF, Lastname GH.
- 5 authors: Lastname AB, Lastname CD Jr, Lastname EF, Lastname GH, Lastname IJ III.
- 6 authors: Lastname AB, Lastname CD Jr, Lastname EF, Lastname GH, Lastname IJ III, Lastname K.

In the reference list, please format other citation information as follows:
- **Journal names**: These are abbreviated according to AMA 14.10, which is identical to the style used by the National Library of Medicine’s PubMed system
Exception: This journal does not italicize the abbreviated journal name and does not have a period after the abbreviated journal names.

- **Abstract references**: These must be given in full, as the abstract may be published separately.

- **Sample citations for print journals**: See AMA 3.11 for guidelines on order of information.

  **Exceptions**: Do not italicize the abbreviated journal name.

  Do not use title case for the article title.

  **Example of reference citation – please note order of elements**
  
  - Last name goes first, followed by initials only for first and second names, if used.
  - Article title does not have each word in uppercase.
  - Journal title abbreviated as per PubMed titles.
  - Journal title is not italicized and takes a period after it.
  - **Year of publication** is listed first and followed by a *semicolon*.
  - The **volume number** (*no space* after semicolon) is followed by the **issue number** in *parenthesis*. There is *no space* between volume number and issue number, and there is a *colon* after the issue number.
  - **Page range** (*no space* after colon) separated by an *en dash* – all digits in the page numbers are given (*100-106, not 100-6*)


- Sample citations for **print books**: See AMA 3.12. *(See exceptions above)*
- Sample citations for **special print materials** and **unpublished material**: See AMA 3.13.
- Sample citations for **media other than print**: See AMA 3.14.
- Sample citations for **electronic references**: See AMA 3.15.
- Sample citations for **legal references**: See AMA 3.15.

**Appendices**

THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY generally does not publish appendices.

**Tables, Figures, and Images**

These features should **supplement**—not reiterate—data and article content. They should provide the reader with easy, at-a-glance access to accurate, succinctly presented data or information.

All visual elements should be numbered according to their order of reference in the text. The text citation should be (Table 3) or (Figure 2).

**Tables.** Tables present data and information that support—but do not reiterate—statements in the running text. Accuracy, clarity, and logical data presentation are of paramount importance in tables. Follow AMA 4.1 for guidance and samples. Specific requirements for THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY include the following:

- **Software**: Create tables using Microsoft Word.
- **Lettering and sizing**: Use uniform lettering in Calibri. Use uniform 9-point type size (to a maximum width of 130 characters).
- **Table title**: Unlike a figure legend, the table title is placed above—not within—the table. The title should be written in headline style and as a brief and descriptive phrase, rather than as a sentence. See 4.1.3 for guidance.
- **Footnotes**: Place table footnotes below the table body, and indicate them with superscript lowercase letters that correspond to the citation in the table body as follows:
  aPhase 2 studies reported treatment-related adverse events; the phase 3 study reported treatment-emergent adverse events. bA comparative effectiveness trial of axitinib and sorafenib.
- **Submission placement**: Tables can be placed at the end of the manuscript document, after the References section.

**Figures and images.** Graphs, maps, flowcharts, illustrations, algorithms, computer-generated images, clinical slide images, photographs are all designated as figures. In general, follow the guidelines and samples in AMA 4.2.

Specific requirements for THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY include the following:

- **Specifications**:
  - Figures (charts, graphs, flowcharts, etc) must be good quality, high-resolution (no less than 350 dpi) PNG files, and must be produced as close as possible to the desired size of the published version. Canvas size of the image should be no less than 5 cm wide. Images with resolutions that are too low, or graphics that are disproportionately large, will not be used.
  - Clinical images must be submitted as original, good quality, high-resolution JPG files. Do not submit them as Word files. Failure to submit good quality files could delay publication of paper.

- **Legends**: Unlike a table title, a figure legend looks like a caption that appears below—not within—the figure. It is written in full sentences (not phrases) of no more than 40 words to describe or explain the figure. See format example below. It includes all symbols, abbreviations, and error bars. See AMA 4.2.7 and the many examples used in AMA 4.2 for guidance.

- **Submission placement**:
  - Figures – submit each figure (each chart, each photo, each graph, image, and so on) as a separate digital file (PNG for charts, graphs, flowcharts, etc; JPG for clinical images or photographs), labeled according to one of the following samples:
    - Authorlastname_Figure 1.png
    - Authorlastname_Figure 2.jpg
  - Note: We do not accept images that are optimized for screen use (eg, in BMP, PICT, or WPG).

**Figure legends** – submit figure legends at the end of the References section of the main article Word file under the heading FIGURE LEGENDS, using the following format:

**FIGURE LEGENDS**

**FIGURE 1** Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

QoL, quality of life; SRS, stereotactic radiosurgery, WBRT, whole-brain radiation therapy

**FIGURE 2** Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.
• **Permissions**: Authors are responsible for obtaining written permission to reproduce figures from other publications.

• **Image manipulation**: Clinical images must be meticulously de-identified. Make sure that information such as patients' images, names, initials, or hospital numbers are not be included in photographs or clinical images, unless the information is essential for scientific purposes and you have obtained written informed consent for publication in print and electronic form from the patient (or parent, guardian or next of kin where applicable). Images must not be manipulated so that they misrepresent the study outcomes or results.

**Abbreviations**
Define abbreviations that are not standard on the first page of the paper. Ensure consistency of abbreviations throughout the paper. In the abstract, unavoidable abbreviations must be defined at their first mention as well.

**Units**
Follow internationally accepted rules and conventions, and use the international system of units (SI). If other units are mentioned, please give their equivalent in SI.

**Footnotes**
*THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY* does not use footnotes. Please incorporate any explanatory material into the text.

**Video Data**
*THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY* accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include these within the body of the article. As with a figure or table, refer to the video or animation content and noting in the body text where it should be placed.

All submitted files should be properly labeled so that they directly relate to the video file's content. To ensure that your video or animation material is directly usable, please provide the files in one of our recommended file formats, with a preferred maximum size of 50 MB.

Video and animation files will be published online in the electronic version of your article. Please supply, good quality original still images with your files; you can choose any frame from the video or animation, or make a separate image. These will be used instead of standard icons, and will personalize the link to your video data.

Note: Because video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Supplementary Data**
*THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY* accepts electronic supplementary material to support and enhance your scientific research. Supplementary files offer the author additional possibilities to publish supporting applications, high-resolution images, background datasets, sound clips, and more.
Supplementary files will be published online alongside the electronic version of your article on the Journal’s site, http://www.jcso-online.com.

To ensure that your submitted material is directly usable, please provide the data in one of our recommended file formats. Authors should submit the material in electronic format together with the article and supply a concise and descriptive caption for each file.

SUBMITTING YOUR MANUSCRIPT

Online Submission of Source Files All THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY manuscripts must be submitted online through Editorial Manager at http://www.editorialmanager.com/jso/.

All tracking and follow-up, from submission, through the peer-review process and revision stage to manuscript acceptance or rejection, will be done through Editorial Manager. The site also provides instructions for manuscript submission and a tutorial for authors at http://www.editorialmanager.com/homepage/docs/Author_Tutorial.pdf.

Required Submission Materials
All manuscript submissions must include the following forms:

- Conflict of interest disclosure form.
- Authorship statement (attestation) form.
- Manuscript submission checklist.

These forms can be downloaded from http://www.editorialmanager.com/jso/. Please scan the completed forms and upload them to Editorial Manager with your submission. Problems? Contact Renee Matthews (Managing Editor) at rmatthews@frontlinemedcom.com, or Susan Hite (Associate Editor, Submissions) at susanhite@frontlinemedcom.com.

File Conversion
The EM automatically converts your manuscript source files to a single PDF file of the paper, which is used in the peer-review process. However, these source files are needed for processing after acceptance. This is why it’s important that you adhere to the AMA style guidelines outlined in the “Preparation of Your Manuscript” section of these guidelines.

Correspondence
All correspondence—including notification of the editor’s decision and requests for revision—takes place by e-mail. There is no paper trail. You can reach Renée Matthews at rmatthews@frontlinemedcom.com.

Submission Checklist
Before you upload your manuscript to Editorial Manager for review, please check the following:

1. **Cover letter**: Is a cover letter included with your manuscript submission?
2. **Title page**: Is the title page presented as outlined on page 8?
3. **Corresponding author**: Have you designated a corresponding author and provided current, correct contact information in the format described in AMA 2.10.4?
4. **Authors**: Have you provided first and last names and highest degrees for each author, according to the formats shown in AMA 2.2.1–2.2.4?
5. **Author affiliations**: Have you included affiliations for each author according to AMA 2.3.3., as well as their current e-mail addresses?
6. **Author disclosures**: Have you included the disclosures and conflicts of interests for all authors?
7. **Word count**: Does the word count include abstract, main running text, references, and tables, and does it appear on the title page of the manuscript?
8. **Formatting:** Is your manuscript double spaced, and have you ensured that it is minimally formatted? (See “Preparation of Your Manuscript.”)

9. **Abstract:** Have you included a structured or unstructured abstract (as stipulated by your article type) that has been formatted according to AMA 2.5 and the specific *THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY* guidelines described in these guidelines?

10. **Reference citations (“callouts”) in running text/tables:** Per AMA chapter 3, are the callouts in superscripts and in numerical order, and does each one match the corresponding reference in the reference list?

11. **Reference list:** Are all references in the reference list complete, accurate, numerically ordered to match the callouts, and formatted according to AMA chapter 3?

12. **Tables:** Have all tables been prepared according to AMA 4.1?

13. **Figures:** Do all figures meet the stated quality requirements to ensure best possible print reproduction? Are their titles and legends formatted according to AMA 4.2? Have they been prepared and uploaded as separate files that are labeled with the correct naming convention?

14. **Permissions:** Have you obtained permission for use of copyrighted material from other sources (including the Web), and have all appropriate forms been completed and included with the submission, according to AMA 5.6?

15. **Final read-through:** Have you checked the spelling and grammar within your manuscript? Does its outline match its content?

---

**AFTER ACCEPTANCE**

**Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI consists of a unique alpha-numeric character string which is assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly “articles in press,” because they have not yet received their full bibliographic information.

When editors use the DOI to create URL hyperlinks to documents on the Web, the DOIs are guaranteed never to change.

**Editing and copy-editing**

After acceptance the article will be edited and copy-edited and returned to the corresponding author for proofing. This may involve requests for additional information or rewording for clarification of meaning. All major edits should occur at this stage.

**Proofs**

After the author has proofed the article, the changes will be incorporated into the parent file and prepared for layout. One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author for a final check. Only minor proofing changes will be accommodated at this stage.

The PDF proofs can be annotated. To access these, you will need to download Adobe Reader version 7 (or higher), which is available free from http://get.adobe.com/reader. To annotate the PDF, you will also need to make a copy of the PDF you receive and save it to your desktop. The PDF you receive serves as the parent file and cannot be changed, only copies of the parent can be changed.) Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site (http://www.adobe.com/products/reader/tech-specs.html).

**PLEASE RETURN THE PROOFED PDF TO THE MANAGER EDITOR, RENEE MATTHEWS (rmatthews@frontlinemedcom.com) WITHIN 24 HOURS OF THEIR RECEIPT.**

If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the Query Form) and return them to rmatthews@frontlinemedcom.com in an e-mail. **Please list your**
corrections by quoting the page AND line number. If for any reason this is not possible, then mark the corrections and any other comments (including replies to the Query Form) on a printout of your proof and return by fax; or scan the pages and return it by e-mail.

Please use this proof only for checking the typesetting, editing, completeness, and correctness of the text, and tables and figures. Significant changes to the article as accepted for publication will be considered at this stage only with permission from the Editor; and if granted, could delay publication. We will do everything possible to get your article published quickly and accurately; please let us have all your corrections within 24 hours.

It is important to ensure that all corrections be sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that we may proceed with the publication of your paper as is if no response is received.

Offprints
The corresponding author, at no cost, will be provided with a PDF file of the article via e-mail. For an extra charge, paper offprints can be ordered via the offprint order form, which is sent once the article is accepted for publication. The PDF file is a watermarked version of the published article and includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions of use.

AUTHOR INQUIRIES
For inquiries relating to the submission of articles (including electronic submission) please visit this journal’s homepage (http://www.jcso-online.com) or e-mail Renée Matthews at rmatthews@frontlinemedcom.com.

Contact details for questions arising after submission or acceptance of a paper, especially those relating to proofs, visit http://www.editorialmanager.com/jso/default.asp, where you can track submitted and accepted by logging in to the Editorial Manager submission platform as an Author.
Original Report [Article Type]

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum [Title; 75 characters max, inc spaces]

Firstname1 Lastname1, MD, a Firstname2 Lastname2, MD, a Firstname3 Lastname3, PhD, b and Firstname4 Lastname4, MD c [Author Names; letter superscripts, comma after degrees, “and” before last name]

a Department of Radiation Oncology, School of Medicine, University of Kentucky, Louisville; and b Department of Family Medicine, University of Minnesota, Minneapolis [Affiliations; letter superscripts]

Accepted for publication Month XX, 2017. Correspondence: David Henry, MD, PhD; e-mail. Disclosures: Dr Smith is a consultant for XXX, the maker of the study drug, and has received research funding from YYY. OR The authors report no disclosures or conflicts of interest. ClinicalTrials.gov identifier: NCT XXX. JCSO 2017;15(XX):eXXX-eXXX. Published online first, Month XX, 2017. ©2017 Frontline Medical Communications. doi: https://doi.org/10.12788/jcso.0XXX

[Structured Abstract, 250 words]

Introduction Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium.

Background Doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore.

Objective Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Methods Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Results Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborumx

Limitations Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed.

Conclusions Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Funding/sponsorship Norvartis sponsored this study.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor unde omnis sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.

Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure ...

Methods [Subhead/sub]
Reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Oluptatem [Subhead 1/sub 1]
Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor unde omnis sit amet, consectetur, adipisci velit, sed quia non numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.

Ut enim ad minima veniam. [Subhead 2/sub2] Quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea
voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

**Quis autem vel eum iure.** Reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

**Ut enim ad minima veniam.** Quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

**Perspiciatis** [Subhead 1/sub 1]
Sed ut unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit, sed quia consequuntur magni dolores eos qui ratione voluptatem sequi nesciunt. Neque porro quisquam est, qui dolorem ipsum quia dolor unde omnis sit amet, consectetur, adipisci velit ...

**Results**
Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

  Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum ...

**Conclusions**
Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur? Quis autem vel eum iure reprehenderit qui in ea voluptate velit esse quam nihil molestiae consequatur, vel illum qui dolorem eum fugiat quo voluptas nulla pariatur?

  Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum ...
Acknowledgment
Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam, nisi ut aliquid ex ea commodi consequatur.

References

FIGURE LEGENDS
FIGURE 1 Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

QoL, quality of life; SRS, stereotactic radiosurgery, WBRT, whole-brain radiation therapy

FIGURE 2 Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore.